Despite the compelling evidence for greater toxicity in female patients, sex-specific anticancer treatment strategies are missing. Increased awareness of sex differences at all stages of drug development by researchers, the pharmaceutical industry, funding institutions and regulatory agencies is needed to accurately implement precision oncology. In this Comment, Berna Özdemir summarizes the evidence for greater drug toxicity in female patients and emphasizes the need for increased awareness of sex differences at all stages of drug development to establish sex-specific anticancer treatment strategies.

中文翻译：

---

消除障碍，解决抗癌药物毒性的性别差异

尽管有令人信服的证据表明女性患者的毒性更大，但仍缺乏针对性别的抗癌治疗策略。为了准确实施精准肿瘤学，研究人员、制药行业、资助机构和监管机构需要提高对药物开发各个阶段性别差异的认识。在这篇评论中，Berna Özdemir 总结了女性患者药物毒性更大的证据，并强调需要在药物开发的各个阶段提高对性别差异的认识，以制定针对性别的抗癌治疗策略。